Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND 61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma

Trial Profile

Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND 61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 26 May 2009 Inclusion and exclusion criteria amended from NCT.
    • 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top